Sign in

    Patrick Dolezal

    Research Analyst at LifeSci Capital

    Patrick Dolezal's questions to Larimar Therapeutics (LRMR) leadership

    Patrick Dolezal's questions to Larimar Therapeutics (LRMR) leadership • Q1 2023

    Question

    Patrick Dolezal from LifeSci Capital questioned if there was a relationship between frataxin levels and injection site reactions, whether similar allergic events were seen in non-human primate studies, and what data would be needed to support chronic dosing.

    Answer

    President and CEO Dr. Carole Ben-Maimon responded that there was no observed relationship between frataxin levels and the mild-to-moderate injection site reactions. She confirmed that similar allergic events were not observed in the non-human primate toxicology studies. Regarding chronic dosing, she indicated that next steps to progress the program would be a topic of discussion in their upcoming FDA meeting.

    Ask Fintool Equity Research AI

    Patrick Dolezal's questions to VYNE Therapeutics (VYNE) leadership

    Patrick Dolezal's questions to VYNE Therapeutics (VYNE) leadership • Q3 2021

    Question

    Patrick Dolezal from LifeSci Capital questioned the known clinical safety effects of the BET inhibitor class and asked what gives VYNE confidence that these can be avoided with VYN201's topical approach and VYN202's selective BD2 approach. He also requested details on the remaining items needed for IND submission for both programs.

    Answer

    Chief Scientific Officer Dr. Iain Stuart addressed safety by explaining that common oral pan-BD inhibitor toxicities (e.g., thrombocytopenia, GI issues) are mitigated in VYN201 through its topical application and a 'soft drug' design that ensures rapid systemic clearance. For VYN202, the high selectivity for BD2 is expected to improve the safety profile, as BD2 is more linked to inflammatory gene signaling than BD1. He also noted that VYN201 showed potency comparable to a super potent steroid in preclinical models. President and CEO Dave Domzalski added that this potency without the associated steroid liabilities is a key reason for the company's enthusiasm.

    Ask Fintool Equity Research AI

    Patrick Dolezal's questions to VYNE Therapeutics (VYNE) leadership • Q2 2021

    Question

    Patrick Dolezal from LifeSci Capital asked how VYNE plans to prioritize its new pipeline to avoid past commercial challenges, specifically questioning why the commercial environment for FMX114 in atopic dermatitis would be different. He also inquired about the Perrigo ANDA filing and its potential impact on the sale of the minocycline portfolio.

    Answer

    President & CEO Dave Domzalski explained the new strategy focuses on NCEs for rare diseases with high unmet needs, which should create a stronger value proposition for payers. He differentiated FMX114 by noting its focus on the mild-to-moderate atopic dermatitis segment, which is less crowded than the moderate-to-severe space. General Counsel Mutya Harsch addressed the ANDA filing, stating it was expected and that the company is confident in its 12 patents. She noted that such litigation is common and potential partners would factor it into any deal structure.

    Ask Fintool Equity Research AI

    Patrick Dolezal's questions to VYNE Therapeutics (VYNE) leadership • Q1 2021

    Question

    Patrick Dolezal from LifeSci Capital requested an update on the phasing out of co-pay card assistance for both AMZEEQ and ZILXI, particularly how the CVS decision impacted timing and revenue per script. He also asked for qualitative feedback on how physicians are receiving and implementing ZILXI in their treatment paradigms.

    Answer

    Chief Commercial Officer Matt Wiley clarified that for commercially covered patients, the co-pay buy-down to $35 will continue for both products. For non-covered patients, the AMZEEQ program is being altered, while the ZILXI program will remain at a $75 out-of-pocket cost for now. Wiley also reported very positive physician feedback on ZILXI, noting it is being used both as a monotherapy and in combination with other regimens, and that its good and growing refill rate is a testament to patient relief.

    Ask Fintool Equity Research AI

    Patrick Dolezal's questions to VYNE Therapeutics (VYNE) leadership • Q3 2020

    Question

    Patrick Dolezal asked about the impact of rising COVID-19 cases on sales force access in specific territories and inquired about the expected seasonality trends for both the acne and rosacea markets.

    Answer

    CEO David Domzalski acknowledged that sales force access varies by region due to COVID-19, with the company pivoting to virtual initiatives where needed, but noted prescription growth continues. CCO Matthew Wiley added that the rosacea market has largely recovered, while the acne market is still down about 10% YoY but improving. He explained acne seasonality peaks with back-to-school (July-August), while rosacea peaks with weather changes in the spring (March-May).

    Ask Fintool Equity Research AI

    Patrick Dolezal's questions to ROCKET PHARMACEUTICALS (RCKT) leadership

    Patrick Dolezal's questions to ROCKET PHARMACEUTICALS (RCKT) leadership • Q2 2021

    Question

    Patrick Dolezal asked if the explanted heart from the Danon patient who received a transplant showed evidence of worsening myocarditis or an immune response, and if similar findings were observed in biopsies from other patients.

    Answer

    CEO Gaurav Shah stated there was no evidence of myocarditis or inflammatory changes in the explanted heart. He also confirmed that similar inflammatory findings were not observed in the biopsies from the other low-dose patients.

    Ask Fintool Equity Research AI

    Patrick Dolezal's questions to Adverum Biotechnologies (ADVM) leadership

    Patrick Dolezal's questions to Adverum Biotechnologies (ADVM) leadership • Q2 2020

    Question

    Patrick Dolezal from LifeSci Capital asked about the envisioned long-term patient monitoring schedule following ADVM-022 administration and whether the need for follow-up visits might negate the benefit of avoiding injections from a patient's perspective.

    Answer

    Chief Medical Officer Aaron Osborne projected an initial period of intensive monitoring, which could then be extended, potentially using home monitoring technologies. Dr. Arshad Khanani strongly supported this, stating that patients are very satisfied with visits that do not involve an injection. He envisions that stable patients could eventually be monitored as infrequently as twice a year, which represents a dramatic improvement in quality of life compared to monthly or bimonthly injection visits.

    Ask Fintool Equity Research AI

    Patrick Dolezal's questions to Adverum Biotechnologies (ADVM) leadership • Q4 2019

    Question

    Patrick Dolezal from LifeSci Capital asked for expectations regarding the ARVO data update given the cancellation of the in-person meeting, and requested additional details on the steroid tapering status for patients in Cohorts 1 and 2.

    Answer

    President and CEO Leone Patterson affirmed the company still plans to present OPTIC trial data in May, utilizing ARVO's virtual presentation options and/or a company-hosted webcast. Chief Medical Officer Aaron Osborne provided a detailed status update: in Cohort 1, three of five non-surgical patients were off steroids completely. In Cohort 2 at 24 weeks, two patients required no steroids post-oral course, two had minimal inflammation treated with short courses, and two were tapering eyedrops for resolving inflammation. He emphasized the inflammation is low-grade, asymptomatic, and manageable.

    Ask Fintool Equity Research AI